Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Bristol-Myers Squibb Builds On Exelixis Collaboration

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Bristol will choose three of Exelixis' pre-IND oncology candidates for a 50/50 development and commercialization deal.

You may also be interested in...



GlaxoSmithKline Passes On Option For Exelixis’ XL647 Lung Cancer Candidate

Exelixis says it will move aggressively to advance EGFR candidate into pivotal trials in first half of 2008 for NSCLC and Phase II for other cancers.

GlaxoSmithKline Passes On Option For Exelixis’ XL647 Lung Cancer Candidate

Exelixis says it will move aggressively to advance EGFR candidate into pivotal trials in first half of 2008 for NSCLC and Phase II for other cancers.

Genentech Kicks Off New Year With Exelixis Deal For MEK Inhibitor

Genentech joins Pfizer and AstraZeneca in developing the new class of oncology compounds.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?

Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

See All
UsernamePublicRestriction

Register

PS063558

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By